Clinical Trial Update: Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating enoblituzumab (MGA271) in combination with pembrolizumab or MGA012 in patients with refractory cancers. Results across melanoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• Enoblituzumab (enoblituzumab)
• MGA012 (MGA012)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: MacroGenics | Conditions: Melanoma, Head and Neck Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-08-11